Duravelo-1 trial showed a 60% overall response rate for zelenectide pevedotin plus pembrolizumab in metastatic urothelial ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in ...

Topline results were announced from a phase 3 trial investigating a subcutaneous formulation of pembrolizumab, a programmed death receptor-1-blocking antibody, with berahyaluronidase alfa ...

Immutep Ltd (AU:IMM) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ®, together with ...

Lenvatinib plus pembrolizumab did not provide benefits over chemotherapy in the overall study cohort, but the combination did provide benefits in subgroups of patients.

During a Case-Based Roundtable® event, Daniel J. George, MD and participants discussed combination regimens for intermediate ...